FDA Approves Wezlana for Multiple Inflammatory Diseases

THURSDAY, Nov. 2, 2023 -- The U.S. Food and Drug Administration has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.  The approval includes indications...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news